Anders G Olsson
Overview
Explore the profile of Anders G Olsson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
3732
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Olsson A
Lakartidningen
. 2021 May;
118.
PMID: 33997946
Two prospective epidemiological studies have pointed to the importance of triglyceride rich lipoproteins in causing atherosclerosis. Lipoprotein analyses show that it is the cholesterol content of the lipoproteins that relates...
3.
Olsson A
Lakartidningen
. 2020 May;
117.
PMID: 32390127
Non-HDL cholesterol concentrations in blood are strongly associated with long-term risk of atherosclerotic cardiovascular disease. A simple tool has been provided for assessment of individual long-term risk and the potential...
4.
Schwartz G, Leiter L, Ballantyne C, Barter P, Black D, Kallend D, et al.
Diabetes Care
. 2020 Mar;
43(5):1077-1084.
PMID: 32144166
Objective: Incident type 2 diabetes is common among patients with recent acute coronary syndrome and is associated with an adverse prognosis. Some data suggest that cholesteryl ester transfer protein (CETP)...
5.
Salahuddin T, Kittelson J, Tardif J, Shah P, Olsson A, Nicholls S, et al.
Am Heart J
. 2020 Jan;
221:60-66.
PMID: 31927126
Background: High-density lipoprotein cholesterol (HDL-C) concentration is inversely related to risk of major adverse cardiovascular events (MACE) in epidemiologic studies but is a poorer predictor of MACE in patients with...
6.
Charytan D, Sabatine M, Pedersen T, Im K, Park J, Lira Pineda A, et al.
J Am Coll Cardiol
. 2019 Jun;
73(23):2961-2970.
PMID: 31196453
Background: Data on PCSK9 inhibition in chronic kidney disease (CKD) is limited. Objectives: The purpose of this study was to compare outcomes with evolocumab and placebo according to kidney function....
7.
Willeit P, Ridker P, Nestel P, Simes J, Tonkin A, Pedersen T, et al.
Lancet
. 2018 Oct;
392(10155):1311-1320.
PMID: 30293769
Background: Elevated lipoprotein(a) is a genetic risk factor for cardiovascular disease in general population studies. However, its contribution to risk for cardiovascular events in patients with established cardiovascular disease or...
8.
Schwartz G, Ballantyne C, Barter P, Kallend D, Leiter L, Leitersdorf E, et al.
JAMA Cardiol
. 2017 Oct;
3(2):164-168.
PMID: 29071331
Importance: It is uncertain whether lipoprotein(a) [Lp(a)], which is associated with incident cardiovascular disease, is an independent risk factor for recurrent cardiovascular events after acute coronary syndrome (ACS). Objective: To...
9.
Rosenson R, Larrey D, Waters D, Olsson A
J Pharm Pract
. 2017 Oct;
31(2):138-139.
PMID: 28974137
No abstract available.
10.
Schwartz G, Fayyad R, Szarek M, DeMicco D, Olsson A
Eur J Prev Cardiol
. 2017 May;
24(12):1294-1296.
PMID: 28504565
Background Early, intensive statin treatment is the standard of care after acute coronary syndrome (ACS). However, the benefit of this approach to prevent major adverse cardiovascular events has been demonstrated...